Curb your marketing
This article was originally published in The Tan Sheet
Executive Summary
Weight-loss patch manufacturer Curb Your Cravings should discontinue its marketing claims until "reliable and competent" testing is conducted on the product, the Electronic Retailing Self-Regulation Program recommends. The Council of Better Business Bureaus subsidiary took issue with the company's emails and online ads that included claims such as "lose up to 30 pounds in 30 days" and "put on the Patch, take off the pounds." Curb Your Cravings' claims were brought to ERSP's attention by a consumer complaint. The company disagrees with ERSP's decision, but "will modify its advertising and discontinue the use of the general performance claims," the firm states...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.